Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16889
Title: Bridging bio-nano science and cancer nanomedicine
Austin Authors: Björnmal, Mattias;Thurecht, Kristofer J;Michael, Michael;Scott, Andrew M ;Caruso, Frank
Affiliation: Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical and Biomolecular Engineering, The University of Melbourne , Parkville, Victoria, Australia
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, The Australian Institute for Bioengineering and Nanotechnology and The Centre for Advanced Imaging, The University of Queensland , Brisbane, Queensland, Australia
Division of Cancer Medicine, Peter MacCallum Cancer Centre , Melbourne, Victoria, Australia
The Peter MacCallum Department of Oncology, The University of Melbourne , Parkville, Victoria, Australia
Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Issue Date: 19-Sep-2017
metadata.dc.date: 2017-09-19
Publication information: ACS Nano 2017; 11(10): 9594-9613
Abstract: The interface of bio-nano science and cancer medicine is an area experiencing much progress but also beset with controversy. Core concepts of the field-e.g., the enhanced permeability and retention (EPR) effect, tumor targeting and accumulation, and even the purpose of "nano" in cancer medicine-are hotly debated. In parallel, considerable advances in neighboring fields are occurring rapidly, including the recent progress of "immuno-oncology" and the fundamental impact it is having on our understanding and the clinical treatment of the group of diseases collectively known as cancer. Herein, we (i) revisit how cancer is commonly treated in the clinic and how this relates to nanomedicine; (ii) examine the ongoing debate on the relevance of the EPR effect and tumor targeting; (iii) highlight ways to improve the next-generation of nanomedicines; and (iv) discuss the emerging concept of working with (and not against) biology. While discussing these controversies, challenges, emerging concepts, and opportunities, we explore new directions for the field of cancer nanomedicine.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16889
DOI: 10.1021/acsnano.7b04855
ORCID: 0000-0002-4100-3131
0000-0002-6656-295X
0000-0002-0197-497X
0000-0002-9876-7079
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/28926225
Type: Journal Article
Subjects: Antibodies
Comparative oncology
Heterogeneity
Metastasis
Nanoengineering
Nanomaterials
Nanoparticles
Tumor targeting
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.